Patents by Inventor Vincenzo Cerundolo

Vincenzo Cerundolo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD FOR IDENTIFYING NEO-ANTIGENS
    Publication number: 20230107853
    Abstract: The present invention relates to a process for identifying and/or isolating T cells which are capable of binding to a tumour in a mammalian subject having the tumour. Such T cells are of use in cancer immunotherapy. The invention also relates to a method of identifying a peptide neo-antigen for use in cancer immunotherapy in a mammalian subject having a tumour.
    Type: Application
    Filed: February 24, 2021
    Publication date: April 6, 2023
    Inventors: Ahmed Ashour AHMED, Donatien CHEDOM-FOTSO, Christopher YAU, Gennaro PROTA, Vincenzo CERUNDOLO, Uzi GILEADI
  • BINDING MOLECULES TO ARGINASE II [ARG2]
    Publication number: 20220403048
    Abstract: An isolated antigen-binding protein characterised in that it is capable of binding specifically to human Arginase II (ARG2) and inhibiting the enzyme activity of human ARG2.
    Type: Application
    Filed: August 21, 2020
    Publication date: December 22, 2022
    Applicants: Cancer Research Technology Limited, Medimmune Limited
    Inventors: Alexandra Addyman, Mark Austin, Michelle Barnard, Vincenzo Cerundolo, Denice Chan, Agata Diamandakis, Sebastian Fielder, Maria Groves, Stuart Haynes, Sarah Holt, Lesley Jenkinson, Stephanie Keswick, Fiona McLaughlin, Pooja Sharma, Yoko Shibata, Louise Slater, Jessica Whitehouse, Mark D Carr, Daniel Burschowsky, Chitra Seewooruthun
  • iNKT cell modulators and methods of using the same
    Patent number: 10765648
    Abstract: Disclosed herein are ?-galactosylceramide (?-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: September 8, 2020
    Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH
    Inventors: Vincenzo Cerundolo, Gurdyal S. Besra, Liam R. Cox
  • INKT CELL MODULATORS AND METHODS OF USING THE SAME
    Publication number: 20190374486
    Abstract: Disclosed herein are ?-galactosylceramide (?-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.
    Type: Application
    Filed: April 17, 2019
    Publication date: December 12, 2019
    Inventors: Vincenzo Cerundolo, Gurdyal S. Besra, Liam R. Cox
  • iNKT cell modulators and methods of using the same
    Patent number: 10314796
    Abstract: Disclosed herein are ?-galactosylceramide (?-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: June 11, 2019
    Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH
    Inventors: Vincenzo Cerundolo, Gurdyal S. Besra, Liam R. Cox
  • Liposomal formulation of nonglycosidic ceramides and uses thereof
    Patent number: 10039715
    Abstract: The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases using the liposomes and compositions of the invention.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: August 7, 2018
    Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
    Inventors: Vincenzo Cerundolo, Simon Eastman
  • INKT CELL MODULATORS AND METHODS OF USING THE SAME
    Publication number: 20170368002
    Abstract: Disclosed herein are ?-galactosylceramide (?-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.
    Type: Application
    Filed: June 7, 2017
    Publication date: December 28, 2017
    Inventors: Vincenzo Cerundolo, Gurdyal S. Besra, Liam R. Cox
  • iNKT cell modulators and methods of using the same
    Patent number: 9700532
    Abstract: Disclosed herein are ?-galactosylceramide (?-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: July 11, 2017
    Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH
    Inventors: Vincenzo Cerundolo, Gurdyal S. Besra, Liam R. Cox
  • LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF
    Publication number: 20170105936
    Abstract: The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases using the liposomes and compositions of the invention.
    Type: Application
    Filed: August 31, 2016
    Publication date: April 20, 2017
    Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
    Inventors: Vincenzo Cerundolo, Simon Eastman
  • INKT CELL MODULATORS AND METHODS OF USING THE SAME
    Publication number: 20160361280
    Abstract: Disclosed herein are ?-galactosylceramide (?-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.
    Type: Application
    Filed: May 12, 2016
    Publication date: December 15, 2016
    Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH
    Inventors: Vincenzo Cerundolo, Gurdyal S. Besra, Liam R. Cox
  • iNKT cell modulators and methods of using the same
    Patent number: 9365496
    Abstract: Disclosed herein are ?-galactosylceramide (?-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: June 14, 2016
    Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH
    Inventors: Vincenzo Cerundolo, Gurdyal S. Besra, Liam Cox
  • INKT CELL MODULATORS AND METHODS OF USING THE SAME
    Publication number: 20150010496
    Abstract: Disclosed herein are ?-galactosylceramide (?-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.
    Type: Application
    Filed: November 30, 2012
    Publication date: January 8, 2015
    Inventors: Vincenzo Cerundolo, Gurdyal S. Besra, Liam Cox
  • LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF
    Publication number: 20140050780
    Abstract: The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases using the liposomes and compositions of the invention.
    Type: Application
    Filed: December 22, 2011
    Publication date: February 20, 2014
    Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
    Inventors: Vincenzo Cerundolo, Simon Eastman
  • Analogs of alpha galactosylceramide and uses thereof
    Patent number: 8334408
    Abstract: Compounds of formula wherein the variables are defined in the specification, are used in compositions which stimulate T cell responses.
    Type: Grant
    Filed: May 4, 2012
    Date of Patent: December 18, 2012
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincenzo Cerundolo, Richard Schmidt, Gopal Reddy, Rengarajan Balamurugan, Gerd Ritter, Gurdyal Besra, Mariolina Salio, Jonathan Silk
  • ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF
    Publication number: 20120269857
    Abstract: Compounds of formula wherein the variables are defined in the specification, are used in compositions which stimulate T cell responses.
    Type: Application
    Filed: May 4, 2012
    Publication date: October 25, 2012
    Inventors: Vincenzo CERUNDOLO, Richard Schmidt, Gopal Reddy, Rengarajan Balamurugan, Gerd Ritter, Gurdyal Besra, Mariolina Salio, Jonathan Silk
  • Materials and methods relating to improved vaccination strategies
    Patent number: 8282935
    Abstract: The invention provides novel vaccination strategies based on a prime-boost vaccination regiment. The inventors have determined improved ways of boosting an immune response in a patient previously primed or exposed to a plurality of epitopes. The improved method requires the epitopes in the boosting phase to be administered individually, i.e. held on separate peptide constructs.
    Type: Grant
    Filed: January 22, 2008
    Date of Patent: October 9, 2012
    Assignee: ISIS Innovation Limited
    Inventors: Vincenzo Cerundolo, Michael J. Palmowski, Edward Man-Lik Choi
  • Analogs of alpha galactosylceramide and uses thereof
    Patent number: 8188313
    Abstract: Compounds of formula wherein the variable are defined in the specification, are used in compositions which stimulate T cell responses.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: May 29, 2012
    Assignees: The University of Birmingham, Chancellor Masters and Scholars of the University of Oxford, Ludwig Institute for Cancer Research
    Inventors: Vincenzo Cerundolo, Richard Schmidt, Gopal Reddy, Rengarajan Balamurugan, Gerd Ritter, Gurdyal Besra, Mariolina Salio, Jonathan Silk
  • ANALOGS OF ALPHA GALACTOSYLCERAMIDE AND USES THEREOF
    Publication number: 20120034269
    Abstract: Compounds of formula wherein the variable are defined in the specification, are used in compositions which stimulate T cell responses.
    Type: Application
    Filed: September 13, 2011
    Publication date: February 9, 2012
    Inventors: Vincenzo Cerundolo, Richard Schmidt, Gopal Reddy, Rengarajan Balamurugan, Gerd Ritter, Gurdyal Besra, Mariolina Salio, Jonathan Silk
  • USE OF INKT OR TLR AGONISTS FOR PROTECTING AGAINST OR TREATING A DISEASE SUCH AS ACUTE INFECTION OR CANCER
    Publication number: 20110293658
    Abstract: A method of protecting a mammalian subject against, or treating, a disease, wherein the mammalian subject has elevated numbers and/or activities of MDSC comprising administering to the subject a pharmaceutically acceptable amount of an iNKT agonist, such as alpha galactosylceramide or an analogue thereof, or a TLR agonist, or a combination thereof.
    Type: Application
    Filed: November 12, 2009
    Publication date: December 1, 2011
    Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
    Inventors: Vincenzo Cerundolo, Carmela De Santo
  • PRODUCTS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE
    Publication number: 20110280930
    Abstract: The present invention provides products which comprise (i) a support and (ii) a BCR-binding antigen attached to the support. The products are capable of BCR-mediated internalization. The products are useful in the induction or augmentation of immune responses, and methods and uses of the products are provided. The present invention also provides methods of delivering an agent preferentially to dendritic cells versus B cells in a population of cells comprising both dendritic and B cells, which methods comprise (i) attaching the agent to a support and (ii) contacting the population of cells with the agent attached to the support, wherein the population of cells comprise B cells and dendritic cells.
    Type: Application
    Filed: May 5, 2009
    Publication date: November 17, 2011
    Inventors: Facundo Batista, Julia Eckl-Dorna, Patricia Barral, Vincenzo Cerundolo